Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.
A new study examines the in vitro antiviral effect of pure budesonide and Pulmicort® against the SARS-CoV-2 WT and two VoCs.
A new paper focuses on the role of corticosteroids, in particular, as these were widely used among patients on intensive respiratory support (IRS).
A Bayesian analysis of the RECOVERY trial suggests the immunosuppressive drug tocilizumab can reduce deaths in hospitalized COVID-19 patients taking corticosteroids as well as patients on oxygen or non-invasive ventilation and likely increases hospital discharge rates. However, it is not clear if patients on invasive ventilation also benefit.
Researchers in Germany and the United States have conducted a study showing that supplementing dexamethasone treatment with Ceylon cinnamon in cases of coronavirus disease 2019 (COVID-19) may allow dexamethasone to be administered at lower doses, thereby avoiding the side effects that occur with high doses of the steroid.
However, a fascinating new study posted to the medRxiv* preprint server suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.
COVID-19 was initially described as lung inflammation, or pneumonia, in older adults. However, we now know that SARS-CoV-2 infections can cause a wide range of symptoms in people of all ages, ranging from no symptoms at all to systemic inflammation and even death.
How does the switch to a high-deductible health plan affect children with asthma? A new study led by researchers at the Harvard Pilgrim Health Care Institute suggests that enrollment in a high-deductible health plan (HDHP) may not be associated with changes in asthma medication use or asthma exacerbations when medications are exempt from the deductible.
A record of medicine utilization patterns assembled by an interdisciplinary team of researchers at the University of California, Irvine and the UC San Diego School of Medicine reveals the thought, care and scientific rigor clinicians at UC Health medical centers applied in their treatment of patients with COVID-19 in 2020.
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.
Researchers have found that the inclusion of a third drug to commonly used dual-drug inhalers can reduce asthma exacerbations and improve control over the disease in children, adolescents, and adults with moderate-to-severe asthma.
Using a laser for a rare brain surgery to treat drop seizures, which cause a child with epilepsy to suddenly fall, holds some advantages over a traditional open craniotomy, including shorter hospital stays for patients, a study led by UT Southwestern researchers indicates.
Human T-cell lymphotropic virus type-1 (HTLV-1) is a retrovirus similar to human immunodeficiency virus (HIV) and has mostly been thought to be transmitted vertically (mother-to-child), or horizontally (sexually or parenterally (e.g. via blood transfusion)).
The ANTICOV clinical trial, conducted in 13 African countries, has started the recruitment of participants to test a new drug combination, nitazoxanide + ciclesonide, to treat people with mild-to-moderate COVID-19 before their cases become severe.
To better understand the COVID-19 clinical feaures associated with mortality, an interdisciplinary team of researchers has investigated important factors and their influence on a patient’s death.
Treatment of an injured or diseased joint may require precise insertion of a syringe needle -- musculoskeletal sonography can help guide clinicians as they drain fluid from arthritic knees or inject corticosteroids into trigger fingers.
The corticosteroid budesonide shows promise in treating patients with mild COVID-19 infection. Interim analysis of the phase 3 PRINCIPLE clinical trial was posted to the medRxiv preprint server. Researchers found a 3-day faster recovery of COVID-19 symptoms in people at high risk for severe side effects administered a budesonide inhaler. There was also a 2.1% reduction in hospitalization and death.
A new study describes the outcome of corticosteroid use in pregnancy.
Fewer patients with severe attacks were seen by their GP or admitted to hospital during the covid-19 pandemic, and fewer were admitted to hospital for pneumonia, influenza and chronic lung diseases, show findings from three papers published online in the journal Thorax.
Corticosteroid anti-inflammatory drugs have been applied to COVID-19 patients over the course of the pandemic, though the results are mixed. In a recent study, the outcomes for such patients are collated, demonstrating a striking correlation between the development of autoantibodies and mortality.